As the novel coronavirus continues to devastate lives and livelihoods across the world, scientists are racing to find a vaccine that could ...
As the novel coronavirus continues to devastate lives and livelihoods across the world, scientists are racing to find a vaccine that could stop its march.
On Monday, India announced its first experimental vaccine to go into human clinical trials in July. It has been jointly developed by a private firm Bharat Biotech and the Indian Council for Medical Research.
The World Health Organisation’s latest draft landscape of Covid-19 candidate vaccines shows 16 candidate vaccines in clinical trials and 125 candidate vaccines in preclinical evaluation.
One of the leading candidates in terms of timing is the University of Oxford-AstraZeneca Covid-19 experimental vaccine, which is already in the stage of human trials. Not far behind is the Moderna vaccine, said WHO chief scientist Soumya Swaminathan last week.
As cautious optimism builds over this global effort, unprecedented in scope, experts also caution that an effective vaccine could never be developed.
While vaccines have been acknowledged as among the greatest public health interventions, there has, arguably, never been so much focus on the development of a single vaccine.
Virologist and Chief Executive Officer of Wellcome Trust/DBT India Alliance, Dr Shahid Jameel, answers some of the most frequently asked questions on vaccine development.
We understand that the candidate vaccines are tested for their ‘immunogenicity’ and ‘protective...
